Business Wire

MN-SMITHS-MEDICAL

16.6.2021 20:02:10 CEST | Business Wire | Press release

Share
Smiths Medical Issues Worldwide Notification Regarding the Recall of Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringe With Skewed Graduation Markings

Smiths Medical has become aware of specific models and lots of Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringes that may exhibit skewed odd number line graduation markings on their syringe barrels. Markings skewed approximately 20 degrees upward have been identified.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005888/en/

Affected Models and Lot Numbers:

Model
Number

Name

Lot Number

4428-1

Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringe 28Gx1/2” 1CC

4046543 and 4062235

4429-1

Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringe 29Gx1/2” 1CC

4014096, 4031846, 4031845, 4040734, 4043536, 4046545, 4046546, 4062239, 4062240, 4062238 and 4062242

Please reference the attachment for an illustration of the skewed graduation marking on the syringe barrel.

As a result of this issue, there is potential for administration of an incorrect dose of insulin, which could result in hyperglycemia (which may lead to ketoacidosis) or hypoglycemia (which may lead to seizures). This may result in serious harm or death.

Smiths Medical has received no reports of death or serious injury related to this issue.

Smiths Medical is issuing Recall Notices and Response Forms to consignees of Affected Models and Lot Numbers to instruct them that they must quarantine and return the product.

Additional Information:

This action has been designated as a Class 1 recall by the U.S. Food and Drug Administration (FDA).

Home Healthcare Environments

The lot number can be found on the packaging for the syringe. Do not use any syringes with the affected lot numbers. The patient or caretaker should contact the pharmacy, home healthcare provider or medical facility that provided the syringe to arrange for return of the syringe and replacement.

Smith Medical Contact Information

Consumers with questions regarding this recall may contact Smiths Medical via telephone at 1-(800)-258-5361.

Consumers may also contact Smiths Medical online at https://smiths-medical.custhelp.com .

Specific questions on the recall should be directed to fieldactions@smiths-medical.com .

FDA MedWatch Reporting

Adverse reactions or quality problems experienced with the use of these products may also be reported to the FDA’s MedWatch Program by:

  • MedWatch website at www.fda.gov/medwatch
  • Phone: 1-800-FDA-1033
  • Fax: 1-800-FDA-0178
  • Mail: MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852

About Smiths Medical

A leading supplier of specialized medical devices and equipment for global markets, focusing on the medication delivery, vital care and safety devices market segments. For more information, visit www.smiths-medical.com .

About Smiths Group

A global technology company that has been operating for nearly 170 years, delivering products and services for the medical technology, security and defense, general industrial, energy and space and commercial aerospace markets worldwide. Smiths Group plc employs c. 23,000 colleagues in over 50 countries and is listed on the London Stock Exchange. For more information visit www.smiths.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Unleashing GEN4: a New Era of High-performance, Sustainable Electric Racing Begins21.4.2026 17:54:00 CEST | Press release

The debut of the GEN4 race car underlines a step change in electric racing performance. Set for its competitive debut in the 2026/27 Season, the GEN4 machine has a 71% increase in power. More road-relevant than ever, many of the biggest OEMs will take these innovations from track to road. The Fédération Internationale de l'Automobile (FIA) and Formula E have unleashed the GEN4 car on track in its debut run in the South of France, signalling the beginning of a new era for electric motor sport. This all-new car will be raced in the 2026/27 Season of the ABB FIA Formula E World Championship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421618886/en/ Unleashing GEN4: A new era of high-performance, sustainable electric racing begins Capable of speeds over 335kph (208mph), 0-100kph in approximately 1.8s, and 0-200kph in just 4.4s - 1.5s faster than its predecessor. GEN4 produces up to 600kW of power, a 71% increase in base ou

Resale on the Rise: Klarna's Resell Feature Grows 75% as Consumers Put Real Money Back in Their Pockets21.4.2026 17:00:00 CEST | Press release

New data from Klarna reveals consumers are making an estimated $137 per sold item as resale becomes a go-to financial habit New data from Klarna,the global digital bank and flexible payments provider, reveals that its in-app resell feature is gaining significant momentum:listings created through the app grew by up to 75% over the past 13 months*, as consumers increasingly turn to resale as a way to earn real money from items they already own. The data points to a broader shift in financial behaviour: consumers are increasingly treating the things they own not as fixed costs, but as assets with ongoing value. Reselling is becoming routine, not a one-off First launched in Sweden in 2022, Klarna's resell feature is now available across 15 markets, letting users list items for resale directly from their purchase history via leading resale marketplaces such as eBay, Poshmark and Tradera. No need to remember what they paid, find the receipt, or switch to another app. Klarna pre-fills key lis

Frasca Pilatus PC-12 PRO Flight Training Device Receives FOCA Qualification21.4.2026 16:05:00 CEST | Press release

Training device developed for the Pilatus PC-12 PRO with Garmin’s G3000 PRIME Integrated Flight Deck Frasca International, Inc., a FlightSafety International company and global leader in flight simulation, today announced that its Pilatus PC-12 PRO Flight Simulation Training Device (FSTD) received Level 2 Flight Training Device (FTD2) and Flight and Navigation Procedures Trainer (FNPT II) qualification from Switzerland’s Federal Office of Civil Aviation (FOCA). Frasca is the first to develop a PC-12 PRO training device. The device equipped with Garmin’s G3000 PRIME Avionics suite is installed at Pilatus Aircraft Ltd headquarters in Stans, Switzerland, where it will support training for the next generation of PC-12 pilots. The qualification enables pilots to complete a wide range of instruments, procedural and advanced systems training in a highly immersive environment that mirrors the capabilities of the aircraft. “The PC-12 PRO leads the way with advanced features, and we’re proud to

Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting21.4.2026 16:00:00 CEST | Press release

- Data from pivotal frontMIND study of tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) featured in oral presentation at ASCO; results support global regulatory submissions Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) will be featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago. “The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma highlight Incyte’s continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “We look forward to sharing the full data at ASCO, and to progressing our pipeline.” Presentation details:

Wolters Kluwer CCH Tagetik Kicks Off Global inTouch 2026 Series Showcasing Expert AI in Action for the Office of CFO21.4.2026 15:28:00 CEST | Press release

Wolters Kluwer CCH Tagetik is set to host Global inTouch 2026, its flagship user conference which takes place May 19–21, 2026, in Lucca, Italy. Celebrating its 20th edition, Global inTouch launches a global event series demonstrating how CCH Tagetik with Expert AI is transforming the way finance works with AI-enabled capabilities embedded directly into the processes that matter most to the office of the CFO. Following the event in Lucca, the Global inTouch showcase will continue with regional inTouch events across key markets worldwide, including Belgium, France, Germany, Japan, the Netherlands, Sweden, the United Kingdom, and the United States. This year’s theme, Own the Future, reflects Wolters Kluwer CCH Tagetik’s commitment to continuous innovation and to empowering finance teams to deliver impact today while confidently shaping what’s next. “The role of the CFO is expanding from reporting on the past to strategically orchestrating the future to maximize value creation,” saidMaria

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye